NCT05102721View on ClinicalTrials.gov

Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 10, 2022

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
DRUG

Avelumab and Pepinemab

IV Infusions every two weeks.

Trial Locations (1)

14642

University of Rochester Medical Center, Rochester

All Listed Sponsors
collaborator

University of Rochester

OTHER

lead

Vaccinex Inc.

INDUSTRY